Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.04.2021 | Case report

Linagliptin/sitagliptin/vildagliptin

Bullous pemphigoid: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Thewjitcharoen Y, et al. Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients. Case Reports in Endocrinology 2020: 8832643, Jan 2020. Available from: URL: http://doi.org/10.1155/2020/8832643 Thewjitcharoen Y, et al. Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients. Case Reports in Endocrinology 2020: 8832643, Jan 2020. Available from: URL: http://​doi.​org/​10.​1155/​2020/​8832643
Metadaten
Titel
Linagliptin/sitagliptin/vildagliptin
Bullous pemphigoid: 5 case reports
Publikationsdatum
01.04.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-94300-7

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Antineoplastics

Case report

BCG